Rituximab (Truxima) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar - Details

Details

Generic Name:
Rituximab
Project Status:
Cancelled
Manufacturer:
Teva Canada Innovation
Brand Name:
Truxima
Project Line:
Reimbursement Review
Project Number:
PC0184-000
Strength:
10 mg/mL
Tumour Type:
Lymphoma & Leukemia
Indications:
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
Funding Request:
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Review Status:
Cancelled
Sponsor:
Teva Canada Innovation
Submission Date (Target Date):

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.